Compositions and methods for treating or preventing diseases of body passageways

• US 6,759,431 B2
• Filed: 08/20/2001
• Issued: 07/06/2004
• Est. Priority Date: 05/24/1996
• Status: Expired due to Fees

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated, University of British Columbia
• Inventors: Hunter, William L., Machan, Lindsay S.
• Primary Examiner(s): Webman, Edward J.
• Application Number:
  US09/933,652
• Publication Number:
  US 20020052404A1
• Time in Patent Office: 1,051 Days
• Field of Search: 514/449, 514/824, 424/501, 424/426, 424/423
• US Class Current: 514/449
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/12 Aerosols; Foams A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5138 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: A61K 9/70 Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug hollow drug-filled fibres A61K9/0092
• CPC Class Codes: A61K 9/7007 : Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 1/00 : Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 : for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/08 : Bronchodilators
• CPC Class Codes: A61P 13/00 : Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 : of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 : of the prostate
• CPC Class Codes: A61P 15/00 : Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 31/04 : Antibacterial agents
• CPC Class Codes: A61P 31/06 : for tuberculosis
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

1. A method for treating or preventing vascular diseases associated with body passageways, comprising delivering to an external portion of the body passageway paclitaxel, or an analogue or derivative thereof.

3. The method according to claim 1 or 2 wherein the paclitaxel, or analogue or derivative thereof further comprises a polymer.

4. The method according to claim 3 wherein the polymer comprises microspheres having an average size ranging from about 0.5 mm to 200 mm.

5. The method according to claim 3 wherein the polymer is a copolymer of lactic acid and glycolic acid.

6. The method according to claim 3 wherein the polymer is poly (caprolactone).

7. The method according to claim 3 wherein the polymer is poly (lactic acid).

8. The method according to claim 3 wherein the polymer is a copolymer of poly (lactic acid) and poly (caprolactone).

9. The method according to claim 3 wherein the polymer is poly(ethylene-vinyl acetate).

10. The method according to claim 3 wherein the polymer is gelatin.

11. The method according to claim 1 or 2 wherein the body passageway is an artery.

12. The method according to claim 1 or 2 wherein the paclitaxel, or analogue or derivative thereof is delivered to an artery via an outer wall of the artery into an adventia.

13. The method according to claim 1 or 2 wherein the vascular disease is stenosis.

14. The method according to claim 1 or 2 wherein the vascular disease is restenosis.

15. The method according to claim 1 or 2 wherein the vascular disease is atherosclerosis.

16. The method according to claim 1 or 2 wherein the body passageway is a vein.

17. The method according to claim 1 or 2 wherein the body passageway is a capillary.

18. The method according to claim 1 wherein the body passageway is an artery.

19. The method according to claim 11 wherein the artery is a coronary artery.

20. The method according to claim 11 wherein the artery is a carotid artery or an aorta.

31. The method according to claims 1, 2, or 21 wherein the paclitaxel, or an analogue or derivative thereof is paclitaxel.

2. A method for treating or preventing vascular diseases associated with body passageways, comprising delivering to smooth muscle cells via the adventia of the body passageway a composition comprising paclitaxel, or an analogue or derivative thereof.

21. A method for treating or preventing disease associated with graft anastomosis, comprising delivering to an external portion of the site of graft anastomosis paclitaxel, or an analogue or derivative thereof.

22. The method according to claim 21 wherein said paclitaxel, or analogue or derivative thereof further comprises a polymer.

23. The method according to claim 22 wherein the polymer is a copolymer of lactic acid and glycolic acid.

24. The method according to claim 22 wherein the polymer is poly (caprolactone).

25. The method according to claim 22 wherein the polymer is poly (lactic acid).

26. The method according to claim 22 wherein the polymer is a copolymer of poly (lactic acid) and poly (caprolactone).

27. The method according to claim 22 wherein the polymer is poly(ethylene-vinyl acetate).

28. The method according to claim 22 wherein the polymer comprises microspheres having an average size ranging from about 0.5 mm to 200 mm.

29. The method according to claim 22 wherein the polymer is in the form of a paste, film, or spray.

30. The method according to claim 21 or 22 wherein the graft is a PTFE graft.